Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Jan;93(1):e70037.
doi: 10.1111/aji.70037.

Efficacy of Corticosteroids in Patients With Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis

Silvia D'Ippolito  1   2 , Filippo Gavi  3 , Chiara Granieri  2 , Chiara De Waure  4 , Sara Giuliano  2 , Francesco Cosentino  1 , Chiara Tersigni  2 , Giovanni Scambia  2   5 , Nicoletta Di Simone  6   7
Affiliations
Meta-Analysis

Efficacy of Corticosteroids in Patients With Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis

Silvia D'Ippolito et al. Am J Reprod Immunol. 2025 Jan.

Abstract

Recurrent pregnancy loss (RPL) represents a complication of pregnancy occurring in 1%-3% of all couples trying to conceive. About 50%-60% of RPL cases remain idiopathic, therefore therapeutic strategies seem empirical and based on unproven evidence. We investigated the efficacy of corticosteroids in women with RPL. We conducted a systematic review and meta-analysis, up to August 2024, in the PubMed, Scopus, and Web of Science databases, including studies on idiopathic RPL women and comparing corticosteroids versus control treatment. Primary outcome was the ongoing pregnancy rate beyond 12 weeks of gestation; secondary outcomes were live birth rate (LBR), stillbirth, birth weight, incidence of preeclampsia and/or gestational diabetes, gestational age at delivery, and fetal abnormalities. Four studies comprising 417 RPL women randomly assigned to steroid or control treatment were included. We found that oral corticosteroids significantly increase the ongoing pregnancy rate beyond 12 weeks of gestation compared to the control group (log OR [odds ratio] = 1.49 [0.32, 2.67], p = 0.01), with high heterogeneity (I2 = 75%), and improve LBR (log OR = 0.9 [0.11, 1.69], p = 0.03), with low heterogeneity (I2 = 0.05%). However, the limited number of studies significantly limits the strength of the findings. Also, the benefit/risk assessment of the use of corticosteroids in early pregnancy for RPL is still unclear.

Keywords: corticosteroids; live birth rate; miscarriage; prednisolone; prednisone; recurrent pregnancy loss.

PubMed Disclaimer

References

    1. M. M. van Dijk, A. M. Kolte, J. Limpens, et al., “Recurrent Pregnancy Loss: Diagnostic Workup After Two or Three Pregnancy Losses? A Systematic Review of the Literature and Meta‐Analysis,” Human Reproduction Update 26 (2020): 356–367.
    1. American College of Obstetricians and Gynecologists. “ACOG Practice Bulletin. Management of Recurrent Pregnancy Loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists.” International Journal of Gynaecology and Obstetrics 78 (2002): 179–190.
    1. ESHRE Guideline Group on RPL, R. Bender Atik, O. B. Christiansen, J. Elson, et al., “ESHRE Guideline: Recurrent Pregnancy Loss: An Update in 2022,” Human Reproduction Open 2023 (2023): hoad002.
    1. L. Regan, R. Rai, S. Saravelos, and T. C. Li, “Royal College of Obstetricians and Gynaecologists. Recurrent Miscarriage (Green‐Top Guideline No. 17),” British Journal of Obstetrics and Gynecology 130 (2023): e9–e39.
    1. G. M. Stirrat, “Recurrent Miscarriage,” Lancet 336 (1990): 673–675.

Substances

LinkOut - more resources